Rus Eng
Main / Company's news / Petr Rodionov participates in the FarmMedProm 2014 conference

Petr Rodionov participates in the FarmMedProm 2014 conference

5 December 2014

On December 3, 2014, Moscow hosted the first FarmMedProm 2014 exhibition and conference where the interim results of the PHARMA-2020 state program were summed up. “Severny” biology and pharmacy cluster represented by MIPT sponsored the event held at the initiative of the Ministry of Industry and Trade of the Russian Federation.

The formal exhibition opening ceremony was attended by Minister of Industry and Trade of the Russian Federation Denis Manturov, Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyb, First Deputy Minister of Health of the Russian Federation Igor Kagramanyan, Deputy Chairman of the Federation Council Committee on Social Policy Lyudmila Kozlova, and Deputy Head of the FMBA of Russia Viktor Nazarov.

One of the first projects to be implemented under the federal program was construction of a full-cycle genetically engineered insulin plant for GEROPHARM. Petr Rodionov, CEO of GEROPHARM, shared his perception of how well the PHARMA-2020 state program is being implemented: “The first impulse to import substitution was given five years ago, when a federal strategy was adopted. To date, this vector is becoming stronger and external circumstances mobilize domestic resources. With the adoption of the federal targeted programme, many companies started to invest in new projects, the investments aimed at supporting the offer on the market: a number of interesting brand new products have already been developed by national manufacturers. Stimulating demand for the products developed under the federal strategy, by means of public procurement, for instance, is becoming a topical issue now.”

“The next step would be developing full-cycle manufacture, manufacture of active pharmaceutical ingredients,” Petr Rodionov adds. “This is the necessary level of localization, because this is the only way the country can reach medicinal independence and security. At the end of last year our full-cycle insulin manufacturing factory, GEROPHARM-Bio, was launched. It manufactures insulin all the way through: from the substance synthesis to the finished dosage form. This is very important because this way we can ensure that critical technologies will be available at all times. By now, we can already satisfy 20% of the insulin needs of the Russian Federation.”

The conference also hosted an exhibition where over 80 Russian pharmaceutical and medical companies participating in the state programme presented their work: medicines and medical equipment.

You are a health care professional?

Go up